ProCE Banner Activity

Prescribing Antiobesity Agents: Is It Worth It?

Clinical Thought
If you had asked me 10 years ago about prescribing antiobesity agents, I would have said, “It’s not worth it.” Today, it’s a different story.

Released: March 27, 2020

Expiration: March 26, 2021

No longer available for credit.

Share

Faculty

Ken Fujioka

Ken Fujioka, MD

Director of Nutrition and Metabolic Research
Diabetes and Endocrine
Scripps Clinic
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk Inc

Faculty Disclosure

Primary Author

Ken Fujioka, MD

Director of Nutrition and Metabolic Research
Diabetes and Endocrine
Scripps Clinic
La Jolla, California

Ken Fujioka, MD, has disclosed that he has received fees for non-CME/CE services from Novo Nordisk and consulting fees from Amgen, Boehringer Ingelheim, Gelesis, Janssen Global, Novo Nordisk, Phenomix, and Sunovion.